|
|
|
|
|
|
|
Highlights from the 2025 APCCC Diagnostics Meeting |
|
|
|
|
| How Do You Diagnose Prostate Cancer? Molecular Tests at Diagnosis for Risk Stratification |
| Gerhardt Attard, MD, PhD |
| Gerhardt Attard's APCCC 2025 presentation highlighted the evolving role of molecular tests for risk stratification in prostate cancer diagnosis, particularly in advanced disease. He emphasized that tumor DNA sequencing is valuable for drug selection, especially in mCRPC, while germline BRCA testing is recommended for all high-risk and M1 patients. |
|
|
|
|
|
| Which Prostate Cancer Risk Group System Is Most Useful for Today? |
| Andrea Gallina, MD |
| Andrea Gallina reviewed prostate cancer risk group systems, highlighting that the ideal classification should use easy-to-obtain variables, provide clear outcomes, and apply across treatment options. While older systems like D’Amico remain widely used, newer tools such as MSKCC nomograms, CAPRA, and CPG offer better precision in predicting prostate cancer death. |
|
|
|
|
|
| Who Needs Additional Imaging for Prostate Cancer Staging? |
| Derya Tilki, MD |
| Derya Tilki emphasized that patients with unfavorable intermediate and high-risk prostate cancer need additional imaging for accurate staging, with PSMA PET/CT strongly recommended due to its superior sensitivity and specificity compared to conventional imaging. Conventional methods like CT and bone scans often miss small lymph node metastases and have limited accuracy, particularly in high-risk patients. |
|
|
|
|
|
|
|
|
|
|
| You Need Next Generation Imaging and It Must be PSMA PET |
| Daniela Oprea-Lager, MD, PhD |
| Daniela Oprea-Lager’s presentation at APCCC Diagnostics 2025 emphasized that for next-generation imaging in prostate cancer, PSMA PET is the gold standard. She highlighted PSMA PET’s superior accuracy in initial staging, recurrence detection, and treatment planning, with clear advantages over conventional imaging, including higher sensitivity and specificity. |
|
|
|
|
|
| Risk Stratification Using a Genomic Classifier for Localized Prostate Cancer: What Is the Added Value?
|
| Daniel Spratt, MD
|
| Daniel Spratt highlighted the added value of using genomic classifiers, particularly Decipher®, to improve risk stratification and personalize treatment for localized prostate cancer. Compared to standard clinical tools like NCCN risk groups, Decipher® provides more accurate prognostic information and helps guide decisions about treatment intensity, such as the duration of androgen deprivation therapy or the need for intensified systemic therapy.
|
|
|
|
|
|
|
|
|
|
|
